Notice of Intent to Publish a Funding Opportunity Announcement for Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)

Notice Number: NOT-DA-20-045

Key Dates
Release Date: March 17, 2020
Estimated Publication Date of Funding Opportunity Announcement : May 01, 2020
First Estimated Application Due Date:July 13, 2020
Earliest Estimated Award Date: April 01, 2021
Earliest Estimated Start Date: April 01, 2021

Related Announcements

Issued by
National Institute on Drug Abuse (NIDA)


The National Institute on Drug Abuse (NIDA) intends to reissue the Funding Opportunity Announcement (FOA) RFA-DA-18-004, "Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)." When reissued, this FOA will continue to utilize the DP2 mechanism.

The purpose of the Avenir Award Program for Substance Use Disorders (SUD) and HIV/AIDS is to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, optimizing therapies for HIV and SUD, reducing the impact of comorbid conditions, and ultimately, eradicating HIV.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in May 2020 with an expected application due date in July 2020.

Ressearch Initiative Details

The Avenir award is designed to support investigators in early stages of their careers who may lack the preliminary data required for an R01 grant, nonetheless propose high priority, high impact research, and show promise of being tomorrow's leaders in the field. Avenir applicants may propose research in any area of high priority HIV/AIDS research ( that has the potential to open new areas of science and/or lead to new avenues for treatment and/or prevention of HIV/AIDS among People Who Use Drugs (PWUD).

The Avenir Award Program for research on the intersection of SUD and HIV/AIDS will support research approaches, both basic and clinical, focused on improving therapies for HIV, preventing HIV transmission, reducing the impact of comorbid conditions, and ultimately, eradicating HIV. Applications responding to this FOA must clearly describe the intersection of SUD with HIV/AIDS. Examples of studies of relevance to drug abuse include: studies using populations with significant numbers of people who use drugs (PWUD) or samples from drug using populations; studies using in vitro systems and/or animal models that test the effects of addictive substances on HIV pathogenesis, disease progression, or treatment; and studies to develop interventions or treatments that are tailored to people who use drugs.

Funding Information
Estimated Total Funding - The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Expected Number of Awards: TBD

Estimated Award Ceiling: Application budgets are limited to $300,000 in Direct Costs each year for up to five years. The maximum amount per award to be funded or awarded annually.
Primary CFDA Numbers: 93.279

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Independent school districts
County governments
Indian/Native American Tribal Government (Federally Recognized)
State Government
For-Profit Organization (Other than Small Business)
Small Business
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Private Institution of Higher Education
Regional Organization
Non-domestic (non-U.S.) Entity (Foreign Organization)
Eligible Agencies of the Federal Government
Applications are not being solicited at this time.


Please direct all inquiries to:

Redonna Chandler, Ph.D.
National Institute on Drug Abuse (NIDA)

Vasundhara Varthakavi, DVM, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146